SCHEMBL22357823

SCHEMBL22357823

Cc1nn(C)c2cc(-c3noc(C4CCN(C(=O)C5CC(=O)N(CC6CC6)C5)CC4)n3)ccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ GRM5 P41594 14/20 0.41
▸ LMNA P02545 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ TUBB4A P04350 1/20 0.39
▸ TUBB P07437 1/20 0.39
▸ TUBA3C P0DPH7 1/20 0.39
▸ TUBA1B P68363 1/20 0.39
▸ TUBA4A P68366 1/20 0.39
▸ TUBB4B P68371 1/20 0.39
▸ TUBB3 Q13509 1/20 0.39
▸ TUBB2A Q13885 1/20 0.39
▸ TUBB8 Q3ZCM7 1/20 0.39
▸ TUBA3E Q6PEY2 1/20 0.39
▸ TUBA1A Q71U36 1/20 0.39
▸ TUBA1C Q9BQE3 1/20 0.39
▸ TUBB6 Q9BUF5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22357966 0.95 SMN1; SMN2 (0.42) SMN1; SMN2ALDH1A1POLBGRM5LMNA
SCHEMBL22357837 0.86 SMN1; SMN2 (0.55) SMN1; SMN2ALDH1A1POLBGRM5LMNA
SCHEMBL30506344 0.85 GRM5 (0.47) SMN1; SMN2GRM5TSHRTUBB4ATUBB
SCHEMBL20116103 0.85 GRM5 (0.47) SMN1; SMN2GRM5TSHRTUBB4ATUBB
SCHEMBL30506241 0.85 GRM5 (0.47) SMN1; SMN2GRM5TSHRTUBB4ATUBB
SCHEMBL20116106 0.85 GRM5 (0.47) SMN1; SMN2GRM5TSHRTUBB4ATUBB
SCHEMBL20116104 0.85 GRM5 (0.47) SMN1; SMN2GRM5TSHRTUBB4ATUBB
SCHEMBL30506259 0.84 USP2 (0.44) SMN1; SMN2ALDH1A1GRM5LMNAHTT
SCHEMBL20116643 0.84 USP2 (0.44) SMN1; SMN2ALDH1A1GRM5LMNAHTT
SCHEMBL22358226 0.84 GRM5 (0.42) SMN1; SMN2ALDH1A1POLBGRM5TUBB4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 SMN1; SMN2 13/4885ALDH1A1 656/4885POLB 3788/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 SMN1; SMN2 13/4885ALDH1A1 656/4885POLB 3788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback